Elevated tumor necrosis factor-α suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma

Stem Cells and Development

Volumn 16, Issue 6, 2007, Pages 921-930

  Li, Bingzong ^a,d   Shi, Mingxia ^a,e   Li, Jing ^a   Zhang, Hongbing ^a   Chen, Bin ^a   Chen, Lei ^b   Gao, Weibo ^a   Giuliani, Nicola ^c   Zhao, Robert Chunhua ^a,b,f,g  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c UNIVERSITY OF PARMA   (Italy)

^d SOOCHOW UNIVERSITY   (China)

^e KUNMING MEDICAL UNIVERSITY   (China)

^f Postdoctoral Research Station Institute of Basic Medicine Sciences CAMS and PUMC   (China)

^g PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN TAZ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE MARROW; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

ADULT; AGED; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KARYOTYPING; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOGENESIS; PROTEINS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 36249023410     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2007.0074     Document Type: Article

References (34)

1. Barille-Nion S and R Bataille. (2003). New insights in myeloma-induced osteolysis. Leuk Lymphoma 44:1463-1467.
2. Bataille R and JL Harousseau. (1997). Multiple myeloma. N Engl J Med 336:1657-1664.
3. Bataille R, D Chappard, C Marcelli, P Dessauw, J Sany, P Baldet and C Alexandre. (1989). Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909-1914.
4. Croucher PI and JF Apperley. (1998). Bone disease in multiple myeloma. Br J Haematol 103:902-910.
5. Callander NS and GD Roodman. (2001). Myeloma bone disease. Semin Hematol 38:276-285.
6. Giuliani N, S Colla and V Rizzoli. (2004). New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-κB ligand (RANKL). Exp Hematol 32: 685-691.
7. Gregory CA, WG Gunn, E Reyes, AJ Smolarz, J Munoz, JL Spees and DJ Prockop. (2005). How wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann NY Acad Sci 1049:97-106.
8. Tian E, F Zhan, R Walker, E Rasmussen, Y, B Barlogie and JD Shaughnessy Jr. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494.
9. Oshima T, M Abe, J Asano, T Hara, K Kitazoe, E Sekimoto, Y Tanaka, H Shibata, T Hashimoto, S Ozaki, S Kido, D Inoue and T Matsumoto T. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106:3160-3165.
10. Komori T. (2005). Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 95:445-453.
11. Franceschi RT and G Xiao. (2003). Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88:446-454.
12. Franceschi RT, G Xiao, D Jiang, R Gopalakrishnan, S Yang and E Reith. (2003). Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 44 (Suppl 1):109-111.
13. Karsenty G. (2000). Role of Cbfa1 in osteoblast differentiation and function. Semin Cell Dev Biol 11:343-346.
14. Giuliani N, S Colla, F Morandi, M Lazzaretti, R Sala, S Bonomini, M Grano, S Colucci, M Svaldi and V Rizzoli. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472-2483.
15. Silvestris F, P Cafforio, N Calvani and F Dammacco F. (2004). Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126:475-486.
16. Nanes MS. (2003). Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321:1-15.
17. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
18. Hong JH, ES Hwang, MT McManus, A Amsterdam, Y Tian, R Kalmukova, E Mueller, T Benjamin, BM Spiegelman, PA Sharp, N Hopkins and MB Yaffe. (2005). TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Scienc 309:1074-1078.
19. Hong JH and MB Yaffe. (2006). TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 5:176-179.
20. Fang B, M Shi, L Liao, S Yang, Y Liu and RC Zhao. (2003). Multiorgan engraftment and multilineage differentiation by human fetal bone marrow Flk1+CD31-CD34-progenitors. J Hematother Stem Cell Res 12: 603-613.
21. - cells. Exp Hematol 31:650-658.
22. Fang B, C Zheng, L Liao, Q Han, Z Sun, X Jiang and RC Zhao. (2005). Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 105:2733-2740.
23. Zhao RC, Y Jiang and CM Verfaillie. (2001). A model of human p210 (bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 97:2406-2412.
24. Cao Y, Z Sun, L Liao, Y Meng, Q Han and RC Zhao. (2005). Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 332:370-379.
25. Gibson UE, CA Heid and PM Williams. (1996). A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001.
26. Wallace SR, MM Oken, KL Lunetta, A Panoskaltsis-Mortari and AM Masellis. (2001). Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91:1219-1230.
27. Gooding RP, A Bybee, F Cooke, A Little, SG Marsh, E Coelho, D Gupta, D Samson and JF Apperley. (1999). Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol 106:669-681.
28. Gilbert L, X He, P Farmer, J Rubin, H Drissi, AJ van Wijnen, JB Lian, GS Stein and MS Nanes MS. (2002). Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277:2695-2701.
29. Valentin-Opran A, SA Charhon, PJ Meunier, CM Edouard and ME Arlot. (1982). Quantitative histology of myeloma-induced bone changes. Br J Haematol 52: 601-610.
30. Rawadi G, B Vayssiere, F Dunn, R Baron and S Roman-Roman. (2003). BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842-1853.
31. Beresford JN, JH Bennett, C Devlin, PS Leboy and ME Owen. (1992). Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 102:341-351.
32. Cerami A, Y Ikeda, N Le Trang, PJ Hotez and B Beutler. (1985). Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 11:173-177
33. Xing H, JP Northrop, JR Grove, KE Kilpatrick, JL Su and GM Ringold. (1997). TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology 138:2776-2783.
34. Takada I, M Suzawa and S Kato. (2005) Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor gamma and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci 97:184-189.